D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$1.2B |
| 2 |
Boston Scientific
BSX
|
+$1.05B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$934M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$924M |
| 5 |
JPMorgan Chase
JPM
|
+$922M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.2B |
| 2 |
NVIDIA
NVDA
|
+$1.58B |
| 3 |
Palantir
PLTR
|
+$901M |
| 4 |
Netflix
NFLX
|
+$883M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$805M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 30.42% |
| 2 | Technology | 18.55% |
| 3 | Consumer Discretionary | 8.97% |
| 4 | Financials | 8.5% |
| 5 | Healthcare | 8.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
551
Bruker Corporation 6.375% Series A Preferred Stock
BRKRP
$1.19B
| $59M | 0.04% |
205,000
| – | – |
2025 Q3
2 quarters
|
|
552
Arcutis Biotherapeutics
ARQT
$3.34B
| $58.8M | 0.04% |
2,496,222
-186,865
| -7% | -$4.77M |
2024 Q1
8 quarters
|
|
553
CALL
CoreWeave
CRWV
$45.3B
| $58.8M | 0.04% |
759,100
-25,900
| -3% | -$2.25M |
2025 Q4
1 quarter
|
|
554
United Therapeutics
UTHR
$23.6B
| $58.8M | 0.04% |
99,106
-207,865
| -68% | -$104M |
2014 Q4
45 quarters
|
|
555
BorgWarner
BWA
$12.5B
| $58.5M | 0.04% |
1,077,520
+946,029
| +719% | +$49.9M |
2025 Q4
1 quarter
|
|
556
Vita Coco
COCO
$3.38B
| $58.2M | 0.04% |
1,214,433
-95,323
| -7% | -$5.2M |
2022 Q3
14 quarters
|
|
557
Commault Systems
CVLT
$6.52B
| $58.1M | 0.03% |
745,556
+733,546
| +6,108% | +$69.6M |
2013 Q2
51 quarters
|
|
558
Rogers Communications
RCI
$16.1B
| $58M | 0.03% |
1,508,717
+1,205,783
| +398% | +$45.9M |
2025 Q3
2 quarters
|
|
559
Brookfield Renewable
BEPC
$5.5B
| $58M | 0.03% |
1,455,939
+792,033
| +119% | +$32.3M |
2024 Q3
6 quarters
|
|
560
BJs Wholesale Club
BJ
$12.5B
| $57.5M | 0.03% |
584,251
-225,945
| -28% | -$21.8M |
2021 Q4
17 quarters
|
|
561
CBRE Group
CBRE
$37.9B
| $57.5M | 0.03% |
424,129
+375,680
| +775% | +$57.1M |
2025 Q2
3 quarters
|
|
562
Enbridge
ENB
$104B
| $57.3M | 0.03% |
1,057,890
+771,527
| +269% | +$39.3M |
2022 Q2
15 quarters
|
|
563
Acuity Brands
AYI
$8.93B
| $57.3M | 0.03% |
204,399
+170,527
| +503% | +$51.8M |
2018 Q1
32 quarters
|
|
564
ConocoPhillips
COP
$161B
| $57.3M | 0.03% |
433,817
-20,699
| -5% | -$2.29M |
2022 Q2
15 quarters
|
|
565
Public Service Enterprise Group
PEG
$36B
| $57.2M | 0.03% |
706,045
-248,702
| -26% | -$20.4M |
2021 Q2
19 quarters
|
|
566
FTI Consulting
FCN
$3.76B
| $57M | 0.03% |
322,665
-106,399
| -25% | -$18.2M |
2020 Q4
21 quarters
|
|
567
PUT
CVS Health
CVS
$110B
| $56.9M | 0.03% |
792,400
-1,081,100
| -58% | -$83.3M |
2013 Q2
51 quarters
|
|
568
Pembina Pipeline
PBA
$27.5B
| $56.8M | 0.03% |
1,270,043
+1,260,143
| +12,729% | +$53.4M |
2022 Q1
16 quarters
|
|
569
CALL
Telus
TU
$12.2B
| $56.8M | 0.03% |
4,417,500
+1,492,500
| +51% | +$20.2M |
2023 Q4
9 quarters
|
|
570
Zoom
ZM
$28.5B
| $56.7M | 0.03% |
705,685
+448,362
| +174% | +$37.6M |
2020 Q1
24 quarters
|
|
571
Kosmos Energy
KOS
$1.57B
| $56.7M | 0.03% |
20,385,745
+14,420,042
| +242% | +$27.1M |
2024 Q3
6 quarters
|
|
572
Mattel
MAT
$4.77B
| $56.4M | 0.03% |
3,883,399
+1,512,537
| +64% | +$27.6M |
2019 Q3
26 quarters
|
|
573
Jazz Pharmaceuticals
JAZZ
$14.2B
| $56.4M | 0.03% |
298,090
+98,788
| +50% | +$17.3M |
2022 Q4
13 quarters
|
|
574
Burlington
BURL
$17.4B
| $56.3M | 0.03% |
172,906
+118,450
| +218% | +$36.3M |
2022 Q4
13 quarters
|
|
575
Zebra Technologies
ZBRA
$18.3B
| $56.3M | 0.03% |
269,069
-230,318
| -46% | -$54.1M |
2024 Q3
6 quarters
|
|
Similar funds
D.E. Shaw & Co's Q1 2026 Portfolio in Review
As of Q1 2026, D.E. Shaw & Co held 5,226 positions worth $166B, down 8.8% from $182B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
D.E. Shaw & Co withdrew a net $5.92B in Q1 2026, closing 756 positions and reducing 1,922 holdings. Its most notable exit was iShares Core S&P 500 ETF, an estimated $805M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 30% of assets, down from 36% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, D.E. Shaw & Co opened a new position in Venture Global Inc worth $211M.
- D.E. Shaw & Co's largest Q1 2026 buy was Venture Global Inc: 13,410,074 shares worth $211M.
- D.E. Shaw & Co added most to Broadcom in Q1 2026, an estimated $1.2B increase.
- D.E. Shaw & Co's biggest Q1 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $3.2B.
- D.E. Shaw & Co fully exited iShares Core S&P 500 ETF in Q1 2026, selling an estimated $805M.
- D.E. Shaw & Co's ten largest holdings make up 11% of its $166B portfolio in Q1 2026.
- D.E. Shaw & Co opened 685 new positions and closed 756 in Q1 2026.
- D.E. Shaw & Co's portfolio value fell 8.8% quarter-over-quarter to $166B.
Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.